Jeff Patton, MD, CEO of OneOncology, joins Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 3 of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Jeff Patton, MD, CEO and board member of OneOncology and executive chairman of Tennessee Oncology, joins hosts Emeline Aviki, MB, MBA, medical director and attending surgeon at NYU Langone Perlmutter Cancer Center, and Stephen Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, for episode 3 of, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Patton, also chairman of the Community Oncology Alliance and a board-certified hematologist and oncologist, highlights of the origins of OneOncology that it was created to protect community oncology, to give other states and communities the opportunity to stay independent in light of large hospital systems, if they wanted to. He also discusses the importance of community clinical trial accrual and of keeping oncological services within the community and not handing them over to large hospital systems, thereby driving up the cost of care.
“OneOncology was created by physicians for physicians to maintain the autonomy and allow physicians the choice of seeing patients in the community vs in a hospital or academic medical center,” he emphasizes. “I think every patient, every family deserves choice. In many cases, and in most cases, we feel like the community option is the best.”
For complete interview audio:
Listen above or on one of these podcast services:
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More